Metastatic HER2-positive breast cancer prognostication from clinical trials may overestimate real-world outcomes due to stricter eligibility criteria, better health status, lower cancer burden, and greater treatment access among trial patients. This evidence concerns the gene ERBB2 and breast cancer.